Dec 10 2009
Boston Scientific Corporation (NYSE: BSX) today announced the pricing of a public offering of $2 billion aggregate principal amount of its senior notes under the Company's shelf registration statement.
The public offering consists of $850 million of 4.50 percent notes due January 2015, $850 million of 6.00 percent notes due January 2020 and $300 million of 7.375 percent notes due January 2040. The Company expects the offering to close on December 14, 2009, subject to standard closing conditions. Boston Scientific plans to use the net proceeds for general corporate purposes, including prepaying a portion of its bank term loan due in April 2011. The Company expects to record a pre-tax charge, not previously anticipated, of approximately $30 million (approximately $19 million after tax, or $0.01 per share) in the fourth quarter associated with the prepayment.
Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification under the securities laws of any such state or jurisdiction. The offering is being made by means of a prospectus and related preliminary prospectus supplement only, copies of which or information concerning this offering may be obtained by contacting the joint bookrunners: Banc of America Securities LLC, Attn: Prospectus Department, 100 West 33rd Street, 3rd Floor, New York, New York 10001, 1-800-294-1322; Deutsche Bank Securities Inc., 100 Plaza One, Floor 2, Jersey City, New Jersey 07311-3901, 1-800-503-4611, [email protected]; or J.P. Morgan Securities Inc., Attn: Syndicate Desk, 270 Park Avenue, 8th floor, NY, NY 10017, 212-834-4533.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information on Boston Scientific, please visit: http://www.bostonscientific.com.
SOURCE Boston Scientific Corporation